TC BioPharm Shares Are Trading Higher After the Company Announced the Execution of a Non-binding Letter of Intent to Acquire a Company Pursuing the Development of Innovative CAR-T Therapies for the Treatment of Refractory Cancers and Solid Tumors.
TC BioPharm Shares Are Trading Higher After the Company Announced the Execution of a Non-binding Letter of Intent to Acquire a Company Pursuing the Development of Innovative CAR-T Therapies for the Treatment of Refractory Cancers and Solid Tumors.
TC BioPharm宣佈執行一份不具約束力的意向書，收購一家致力於開發治療難治性癌症和實體瘤的創新CAR-T療法的公司，此後，該公司股價走高。
TC BioPharm Shares Are Trading Higher After the Company Announced the Execution of a Non-binding Letter of Intent to Acquire a Company Pursuing the Development of Innovative CAR-T Therapies for the Treatment of Refractory Cancers and Solid Tumors.
TC BioPharm宣佈執行一份不具約束力的意向書，收購一家致力於開發治療難治性癌症和實體瘤的創新CAR-T療法的公司，此後，該公司股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。